Enbrel (etanercept) Letter of Medical Necessity
Enbrel (etanercept) is a first-generation TNF inhibitor that remains widely prescribed but increasingly faces biosimilar substitution pressure. A targeted LMN addressing biosimilar exemption rationale is often required.
FDA-Approved Indications
- ● rheumatoid arthritis
- ● juvenile idiopathic arthritis
- ● psoriatic arthritis
- ● ankylosing spondylitis
- ● plaque psoriasis
Why Enbrel Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. csDMARD trial not documented
- 2. Biosimilar (Erelzi, Eticovo) preferred
- 3. TB screening missing
- 4. Diagnosis ICD-10 not specific enough
- 5. Concurrent biologic use
What to Include in a Enbrel Letter of Medical Necessity
Document confirmed inflammatory arthritis or psoriasis diagnosis, csDMARD trials, baseline severity, TB clearance, and any clinical rationale for the originator over biosimilars (e.g., prior intolerance to a specific excipient).
Key clinical evidence to cite:
- ✓ TEMPO, COMET, and PRESERVE trials
- ✓ Long-term registry data >20 years
- ✓ Pediatric efficacy and safety data
Relevant guidelines:
- 📖 ACR 2021 RA Guidelines
- 📖 ACR 2019 JIA Guidelines
- 📖 AAD-NPF Psoriasis Guidelines
Enbrel Prior Authorization Criteria
Standard criteria across major US payers for Enbrel. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → csDMARD trial not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Enbrel
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Enbrel Prior Authorization FAQ
Why was my Enbrel prior authorization denied?
The most common denial reasons for Enbrel are: csDMARD trial not documented; Biosimilar (Erelzi, Eticovo) preferred; TB screening missing; Diagnosis ICD-10 not specific enough; Concurrent biologic use.
What should a Enbrel Letter of Medical Necessity include?
Document confirmed inflammatory arthritis or psoriasis diagnosis, csDMARD trials, baseline severity, TB clearance, and any clinical rationale for the originator over biosimilars (e.g., prior intolerance to a specific excipient).
Which payers cover Enbrel?
Enbrel is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.